

ST. JUDE MEDICAL, INC.

SJM CONFIRM (DM2102) ICM  
510(k) PREMARKET NOTIFICATION

**SECTION 5**  
**510(k) SUMMARY (CONT.)**

---

**510(k) Notification K** \_\_\_\_\_

**GENERAL INFORMATION**

**Applicant:**

St. Jude Medical, Inc.  
645 Almanor Avenue  
Sunnyvale, CA 94085  
USA  
Phone: (408) 738-4883  
Fax: (408) 735-8750

**Contact Person:**

Michael McSweeney  
Regulatory Affairs  
St. Jude Medical, Inc.  
645 Almanor Avenue  
Sunnyvale, CA 94085  
USA  
Phone: (408) 522-6112  
Fax: (818) 256-8795  
Email: mmcsweeney@sjm.com

**Date Prepared:** November 13, 2013

**DEVICE INFORMATION**

**Trade Name:**

SJM Confirm™ Implantable Cardiac Monitor (ICM), Model DM2102

**Generic/Common Name:**

Cardiovascular Monitoring Device

**Classification:**

21 CFR §870.2800, Medical magnetic tape recorder, Class II  
21 CFR §870.2920, Telephone electrocardiograph transmitter and receiver, Class II

**Product Code:**

MXC

**SECTION 5**  
**510(k) SUMMARY (CONT.)**

---

**PREDICATE DEVICE(S)**

- St. Jude Medical, Inc. SJM Confirm (DM2100) ICM (K122161)
- St. Jude Medical, Inc. SJM Confirm (DM2100) ICM (K122090)
- Medtronic, Inc. Reveal XT Insertable Cardiac Monitor (K082475)
- St. Jude Medical, Inc. SJM Confirm (DM2100) ICM (K081365)

**INDICATIONS FOR USE**

The SJM Confirm™ ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for other cardiac arrhythmias.

The SJM Confirm ICM, Model DM2102, is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.

**PRODUCT DESCRIPTION**

The SJM Confirm ICM is a cardiovascular monitoring device used to record and play back physiological signals.

**TECHNOLOGICAL CHARACTERISTICS**

The technological characteristics of the SJM Confirm ICM are similar to the predicate devices. Performance data were provided to support the determination of substantial equivalence.

**SUBSTANTIAL EQUIVALENCE**

The SJM Confirm ICM is substantially equivalent to the SJM Confirm (DM2100) ICM (K122161), the SJM Confirm (DM2100) ICM (K122090), the Medtronic, Inc. Reveal XT Insertable Cardiac Monitor (K082475), and the SJM Confirm (DM2100) ICM (K081365). The subject and the predicate devices are cardiovascular monitoring devices used to record and play back physiological signals. The indications for use for the SJM Confirm ICM are substantially equivalent to the indications for use for the predicate devices. Any differences in the technological characteristics between the devices do not raise any new issues of safety or effectiveness. Thus, the SJM Confirm ICM is substantially equivalent to the predicate devices.

**TESTING IN SUPPORT OF SUBSTANTIAL EQUIVALENCE DETERMINATION**

All necessary nonclinical and clinical testing was conducted on the SJM Confirm ICM to support a determination of substantial equivalence to the predicate devices, including:

- Software Verification and System Validation
- Clinical Study

There are no changes to the hardware, firmware, materials, manufacturing processes, sterilization, shelf life, or packaging of the SJM Confirm (DM2102) ICM as compared to the cleared SJM Confirm (DM2100) ICM included in this submission. Therefore, biocompatibility, sterilization, shelf life, packaging, electromagnetic compatibility (EMC), electrical safety, mechanical performance, firmware, component, and usability testing was not repeated since clearance of K122161, K122090, and K081365.

**SECTION 5**  
**510(k) SUMMARY (CONT.)**

---

Software testing, system validation testing, and clinical performance testing were performed to demonstrate the SJM Confirm ICM meets the required performance criteria to support a determination of substantial equivalence to the predicate devices.

The results of testing show that the SJM Confirm ICM performs as intended and is safe for its intended use.

**CONCLUSION**

The SJM Confirm ICM is an implantable cardiovascular monitoring device and shares its design and mechanism of action with the identified predicate devices. The results of nonclinical and clinical testing demonstrate that the SJM Confirm ICM functions to its specifications, performs as intended, and exhibits the appropriate characteristics of an implantable cardiovascular monitoring device. The SJM Confirm ICM is substantially equivalent to the predicate devices in terms of technological characteristics, intended use, and performance. No new issues of safety or effectiveness are raised by the SJM Confirm ICM.

**SUMMARY**

The SJM Confirm ICM is substantially equivalent to the predicate devices.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66 G609  
Silver Spring, MD 20993-0002

May 28, 2014

St. Jude Medical, Inc.  
Michael Mc Sweeney  
645 Almanor Avenue  
Sunnyvale, CA 94085 US

Re: K133481  
Trade/Device Name: SJM Confirm Implantable Cardiac Monitor (ICM, Model DM2102)  
Regulation Number: 21 CFR 870.2800  
Regulation Name: Implantable Cardiac Monitor  
Regulatory Class: Class II  
Product Code: MXC  
Dated: May 5, 2014  
Received: May 2, 2014

Dear Michael Mc Sweeney,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the [Federal Register](#).


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems

(QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A stylized signature of Bram D. Zuckerman, consisting of the letters 'B', 'D', and 'Z' intertwined in a graphic, handwritten style.

for Bram D. Zuckerman, M.D.

Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

K133481

ST. JUDE MEDICAL, INC.

SJM CONFIRM (DM2102) ICM  
510(k) PREMARKET NOTIFICATION

**SECTION 4**  
**INDICATIONS FOR USE STATEMENT**

---

510(k) Number (if known): K133481

Device Name: SJM Confirm Implantable Cardiac Monitor (ICM), Model DM2102

**Indications For Use:**

The SJM Confirm™ ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for other cardiac arrhythmias.

The SJM Confirm ICM, Model DM2102, is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.

Prescription Use X  
(21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use \_\_\_\_\_  
(21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF  
NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

A handwritten signature in black ink is written over a circular stamp. The stamp contains the text "Date: 2014.05.28 17:42:42 -04'00'". The signature appears to be "Michael S. ...".